{"type":"trials","record":{"id":41948,"source_id":"clinicaltrials-gov","external_id":"NCT06487039","title":"Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration","brief_summary":"Trial to Evaluate the Safety and Efficacy of EB-203 in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to primarily investigate the safety and tolerability of EB-203 by dose in patients with neovascular Age-related Macular Degeneration (nAMD), and to secondarily evaluate the clinical efficacy. Subject to Adults aged 50 years or older and Neovascular age-related macular degeneration (nAMD)","overall_status":"Unknown","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"EyebioKorea, Inc.","enrollment":50,"countries":["South Korea"],"start_date":"2024-08-01","completion_date":"2026-01-01","last_update_date":"2024-08-27","source_url":"https://clinicaltrials.gov/study/NCT06487039","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"EyebioKorea, Inc.","interventions":["EB-203"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in central retinal thickness (CRT) — Week 12","Change in BCVA — Weeks 4, 8, 12","Change Proportion (%) in BCVA — Weeks 4, 8, 12","Proportion (%) of subjects with complete disappearance of intraretinal and subretinal fluid — Weeks 4, 8, 12","Proportion (%) of subjects who received rescue medication — Weeks 4, 8, 12"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration (nAMD)","EB-203"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06487039","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-08-01 to 2026-01-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.897Z","intervention":["EB-203"],"participants":50,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in central retinal thickness (CRT) — Week 12","Change in BCVA — Weeks 4, 8, 12","Change Proportion (%) in BCVA — Weeks 4, 8, 12","Proportion (%) of subjects with complete disappearance of intraretinal and subretinal fluid — Weeks 4, 8, 12","Proportion (%) of subjects who received rescue medication — Weeks 4, 8, 12"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41948","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}